Table 2.
ΔCT expression of mRNA in ileal biopsies of HC, and IBS-C and IBS-D patients; a lower ΔCT between 2 groups implies higher expression
| Symbol | ΔCT health | ΔCT IBS-C | ΔCT IBS-D | P ANOVA | P health vs IBS-C | P health vs IBS-D | P IBS-C vs IBS-D | Expression IBS-C vs HC IBS-D vs IBS-C |
| Cell adhesion, tight junctions, or barrier function | ||||||||
| TFF1 | 4.29 ± 0.20 | 5.08 ± 0.18 | 4.00 ± 0.28 | 0.002 | 0.022 | 0.645 | 0.004 | ↓IBS-C; ↑IBS-D |
| FN1 | 7.25 ± 0.21 | 7.73 ± 0.18 | 6.94 ± 0.21 | 0.029 | 0.096 | 0.320 | 0.027 | ↑ IBS-D |
| CLDN1 | 11.10 ± 0.30 | 11.82 ± 0.28 | 10.71 ± 0.43 | 0.063 | 0.096 | 0.452 | 0.033 | ↑ IBS-D |
| CLDN12 | 7.15 ± 0.16 | 7.53 ± 0.15 | 7.03 ± 0.16 | 0.066 | 0.088 | 0.620 | 0.035 | ↑ IBS-D |
| PVRL3 (Nectin3) | 5.12 ± 0.14 | 5.45 ± 0.10 | 5.03 ± 0.14 | 0.049 | 0.134 | 0.895 | 0.068 | |
| OCLN | 5.02 ± 0.16 | 5.21 ± 0.14 | 4.80 ± 0.21 | 0.241 | 0.38 | 0.403 | 0.060 | |
| MYLK | 5.44 ± 0.16 | 5.82 ± 0.16 | 5.37 ± 0.18 | 0.124 | 0.022 | 0.786 | 0.087 | ↓ IBS-C |
| TJP1 | 6.10 ± 0.17 | 6.26 ± 0.07 | 5.75 ± 0.16 | 0.034 | 0.643 | 0.187 | 0.027 | ↑ IBS-D |
| FGFR4 | 10.95 ± 0.20 | 10.87 ± 0.11 | 10.41 ± 0.31 | 0.127 | ns | 0.097 | 0.099 | |
| Neurotransmitters, exchangers, and receptors | ||||||||
| GPBAR1 | 11.74 ± 0.16 | 12.31 ± 0.14 | 11.95 ± 0.17 | 0.032 | 0.027 | 0.657 | 0.258 | ↓ IBS-C |
| HNMT | 10.05 ± 0.24 | 10.59 ± 0.16 | 10.08 ± 0.28 | 0.133 | 0.066 | 0.919 | 0.114 | |
| HRH1 | 8.20 ± 0.12 | 8.30 ± 0.11 | 8.02 ± 0.24 | 0.196 | 0.539 | 0.483 | 0.09 | |
| HRH2 | 11.50 ± 0.32 | 12.14 ± 0.59 | 10.96 ± 0.33 | 0.205 | 0.677 | 0.251 | 0.067 | |
| SLC9A1 | 8.12 ± 0.12 | 7.75 ± 0.10 | 7.71 ± 0.36 | 0.089 | 0.020 | 0.529 | 0.54 | ↑ IBS-C |
| KITLG | 6.63 ± 0.17 | 7.03 ± 0.13 | 6.29 ± 0.13 | 0.005 | 0.120 | 0.301 | 0.004 | ↑ IBS-D |
| INADL (PATJ) | 7.25 ± 0.10 | 6.92 ± 0.09 | 7.11 ± 0.29 | 0.157 | 0.018 | 0.494 | 0.888 | ↑ IBS-C |
| SOS1 | 6.18 ± 0.17 | 6.31 ± 0.07 | 5.98 ± 0.14 | 0.230 | 0.470 | 0.402 | 0.034 | ↑ IBS-D |
| Cell kinetics | ||||||||
| CTNNB1 | 6.58 ± 0.11 | 6.26 ± 0.09 | 6.47 ± 0.24 | 0.185 | 0.033 | 0.338 | 0.707 | ↑ IBS-C |
| CALR | 3.81 ± 0.16 | 4.10 ± 0.07 | 3.46 ± 0.11 | 0.002 | 0.162 | 0.107 | 0.001 | ↑ IBS-D |
| PPP1CB | 2.69 ± 0.10 | 2.83 ± 0.04 | 2.61 ± 0.07 | 0.099 | 0.117 | 0.518 | 0.008 | ↑ IBS-D |
| Innate immunity and inflammation | ||||||||
| TLR1 | 10.51 ± 0.34 | 11.17 ± 0.31 | 10.20 ± 0.50 | 0.237 | 0.162 | 0.891 | 0.094 | |
| TLR3 | 6.60 ± 0.13 | 7.07 ± 0.18 | 6.83 ± 0.22 | 0.143 | 0.050 | 0.347 | 0.407 | ↓ IBS-C |
| TLR5 | 10.76 ± 0.24 | 11.14 ± 0.20 | 10.57 ± 0.23 | 0.191 | 0.238 | 0.580 | 0.079 | |
| IL15 | 8.67 ± 0.16 | 8.98 ± 0.12 | 8.62 ± 0.14 | 0.139 | 0.117 | 0.835 | 0.068 | |
CALR, calreticulin; CLDN1, claudin-1; CLDN12, claudin-12; CTNNB1, catenin beta 1; FGFR4, fibroblast growth factor receptor 4; FN1, fibronectin 1; GPBAR1, G-protein–coupled bile acid receptor 1; HC, healthy controls; HNMT, histamine n-methyl transferase; HRH1, histamine receptor H1; HRH2, histamine receptor H2; IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; IL15, interleukin 15; INADL, inactivation-no-afterpotential D-like (also known as PATJ); KITLG, KIT ligand; mRNA, messenger RNA; MYLK, myosin light chain kinase; OCLN, occludin; PPP1CB, protein phosphatase 1 catalytic subunit beta; PVRL3, poliovirus-receptor-related 3 (also known as nectin 3); SLC9A1, solute carrier family 9 member A1; SOS1, Sons of Sevenless (Drosophila) homolog 1; TFF1, trefoil factor 1; TJP1, tight junction protein 1; TLR1, toll-like receptor 1; TLR3, toll-like receptor 3; TLR5, toll-like receptor 5; ΔCT, change in calculation of the threshold cycle.